Geneoscopy Attracts Funding From SINC Fund and Varia Ventures 

The SINC Fund, a venture capital fund sponsored by SAGES Ingenuity Inc., and Varia Ventures Management Company LLC have invested in Geneoscopy Inc., a life sciences company developing diagnostic tests for gastrointestinal diseases.

“Having the SINC Fund join our Series C funding round is a powerful endorsement of Geneoscopy’s technology and mission,” Geneoscopy CEO Andrew Barnell said. “Their support—especially from members on the front lines of patient experience and gastrointestinal care—reinforces the impact our innovations can have in improving patient outcomes.”

Geneoscopy’s most notable solution is the U.S. Food and Drug Administration-approved ColoSense test, a non-invasive, stool-based colorectal cancer screening assay. The company’s technology platform uses proprietary RNA biomarker analysis to provide accurate and reliable diagnostic information to screen for cancer and precancerous polyps (advanced adenomas). The Series C funding to which the SINC Fund and Varia Ventures contributed will support ColoSense’s commercial launch and advance research into diagnostic testing for inflammatory bowel disease.

“Geneoscopy’s ColoSense test represents a significant leap forward in non-invasive colorectal cancer screening,” stated S.D. Schwaitzberg, M.D., chair of the SINC Fund Investment Committee. “By providing accurate and accessible diagnostic information, Geneoscopy empowers both patients and physicians to take proactive steps in managing gastrointestinal health. We are proud to support their mission through the SINC Fund.”

The SINC Fund was launched to allow SAGES members and others to invest in a venture fund with a portfolio of startups primarily in the therapeutic GI/GI surgery space. The investment in Geneoscopy aligns with SAGES Ingenuity’s mission to foster innovation in surgical and gastroenterological care by providing critical funding and support to promising early-stage companies.

The Society of American Gastrointestinal and Endoscopic Surgeons (SAGES) is a surgical society representing more than 7,000 surgeons who bring minimal access surgery and emerging techniques to patients worldwide. SAGES innovates, educates, and collaborates to improve patient care with a vision of reimagining surgical care for a healthier world.

Varia Ventures is a venture capital firm that partners with globally recognized thought leaders, medical and surgical societies, and others to manage venture funds in their fields of expertise.

Geneoscopy Inc. develops diagnostic tests for gastrointestinal health. Leveraging its proprietary, patented stool-derived eukaryotic RNA (seRNA) biomarker platform, Geneoscopy’s aims to empower patients and providers to transform gastrointestinal health through diagnostics.